VBI Vaccines is a leading biopharmaceutical company that specializes in the development and production of vaccines. Their flagship product, PreHevbrio, is an FDA-approved 3-antigen hepatitis B vaccine designed to prevent infection caused by all known subtypes of the hepatitis B virus. With a focus on improving immunogenicity and addressing the needs of high-risk populations, VBI Vaccines aims to provide effective and safe solutions for the prevention of hepatitis B infection.
Committed to public health, VBI Vaccines recognizes the ongoing threat of hepatitis B and the low vaccination rates in the United States. By delivering the Power of 3 through their innovative 3-antigen design, PreHevbrio offers enhanced protection against hepatitis B, particularly in vulnerable groups such as those with advanced age, diabetes, high BMI, and immunosuppression. With a dedication to safety and efficacy, VBI Vaccines strives to make a significant impact in the fight against hepatitis B and improve the overall health and well-being of individuals.
Generated from the website